89BIO
89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH. We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).
89BIO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.89bio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
238.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Aerial BioPharma
Aerial BioPharma is a biopharmaceutical company developing biologics and small molecules for central nervous system issues.
BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Series A - 89bio
Longitude Capital
Longitude Capital investment in Series A - 89bio
OrbiMed
OrbiMed investment in Series A - 89bio
Pontifax
Pontifax investment in Series A - 89bio
Official Site Inspections
http://www.89bio.com Semrush global rank: 3.7 M Semrush visits lastest month: 3.75 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "89bio"
Investors – 89bio, Inc.
Feb 6, 2025 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic …See details»
89bio - Crunchbase Company Profile & Funding
Organization. 89bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... 89bio is a clinical-stage …See details»
89bio - LinkedIn
89bio | 12,143 followers on LinkedIn. Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases | 89bio is a clinical-stage biopharmaceutical ...See details»
89bio, Inc. Company Profile | San Francisco, CA | Competitors ...
Find company research, competitor information, contact details & financial data for 89bio, Inc. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
89bio - Funding, Financials, Valuation & Investors - Crunchbase
Their latest funding was raised on Jan 28, 2025 from a Post-IPO Equity round. 89bio is registered under the ticker NASDAQ:ETNB . Their stock opened with $16.00 in its Nov 11, 2019 IPO. …See details»
89bio - Contacts, Employees, Board Members, Advisors & Alumni
89Bio is a biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders. ... Experience the new Crunchbase, powered by …See details»
89bio - The Org
Powerful ScienceMeaningful MedicinesChanging Lives 89bio is a clinical-stage biopharma company focused on the development and commercialization of innovative therapies for …See details»
Press Releases | 89bio, Inc.
Jan 27, 2025 SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused …See details»
89bio, Inc. - AnnualReports.com
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89 …See details»
Powerful Science – Meaningful Medicines – Changing …
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates. 02/06/2025 PRESS RELEASE. 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [email protected]. …See details»
89bio, Inc.
89bio, Inc. (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are 001-39122 36-4946844 (State or othe r jur i s di c ti on ... closely with its contract research …See details»
89bio, Inc. (ETNB) Company Profile & Facts - Yahoo Finance
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The …See details»
89bio Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 89Bio is a clinical-stage biopharmaceutical company. The company mainly addresses urgent needs in the liver and metabolic disorders by the development of the …See details»
89bio - Israeli Startup | Startup Nation Finder
Feb 20, 2025 Note that you need to have an email in this organization in order to claim the profile. Name* Work Email* (please provide your email in the organization) Position* Notes. …See details»
89bio Provides Business Update and Outlook for 2025
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment …See details»
Powerful Science – Meaningful Medicines – Changing Lives - 89bio
Clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat people with liver and cardiometabolic diseases.See details»
89bio, Inc. (NASDAQ:ETNB) Shares Purchased by JPMorgan
1 day ago JPMorgan Chase & Co. lifted its stake in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) by 210.1% during the 4th quarter, according to the company in its most recent 13F …See details»
89bio Announces U.S. FDA has Granted Breakthrough Therapy …
Sep 21, 2023 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal …See details»
Working at 89bio - Great Place To Work®
Great Place To Work Certification criteria are the global standard for quantifying and benchmarking the employee experience. Using the Great Place To Work Trust Model and the …See details»
ETNB - 89Bio, Inc. Latest Stock News & Market Updates
Mar 3, 2025 Overview. 89Bio, Inc. (symbol: ETNB) is a United States-based clinical-stage biopharmaceutical company committed to advancing innovative therapies for patients with liver …See details»